Otvos L - Search Results

1

Molecular targeting of obesity pathways in cancer.

Surmacz E, Otvos L. Surmacz E, et al. Among authors: otvos l. Horm Mol Biol Clin Investig. 2015 May;22(2):53-62. doi: 10.1515/hmbci-2015-0007. Horm Mol Biol Clin Investig. 2015. PMID: 25879324 Review.

2

Targeting the leptin receptor: a potential new mode of treatment for breast cancer.

Otvos L Jr, Surmacz E. Otvos L Jr, et al. Expert Rev Anticancer Ther. 2011 Aug;11(8):1147-50. doi: 10.1586/era.11.109. Expert Rev Anticancer Ther. 2011. PMID: 21916566 No abstract available.

3

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling.

Otvos L Jr, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI, Hoffmann R, Wade JD, Lovas S, Surmacz E. Otvos L Jr, et al. Biopolymers. 2015 May;104(3):156-66. doi: 10.1002/bip.22627. Biopolymers. 2015. PMID: 25683126

4

Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation.

Otvos L Jr, Kovalszky I, Scolaro L, Sztodola A, Olah J, Cassone M, Knappe D, Hoffmann R, Lovas S, Hatfield MP, Beko G, Zhang S, Wade JD, Surmacz E. Otvos L Jr, et al. Biopolymers. 2011;96(2):117-25. doi: 10.1002/bip.21377. Biopolymers. 2011. PMID: 20564005

5

Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.

Otvos L Jr, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E. Otvos L Jr, et al. Eur J Cancer. 2011 Jul;47(10):1578-84. doi: 10.1016/j.ejca.2011.01.018. Epub 2011 Feb 23. Eur J Cancer. 2011. PMID: 21353530

6

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E. Otvos L Jr, et al. BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90. BMC Biotechnol. 2011. PMID: 21974986 Free PMC article.

7

Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity.

Beccari S, Kovalszky I, Wade JD, Otvos L Jr, Surmacz E. Beccari S, et al. Among authors: otvos l jr. Peptides. 2013 Jun;44:127-34. doi: 10.1016/j.peptides.2013.03.027. Epub 2013 Apr 6. Peptides. 2013. PMID: 23567149

8

The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor.

Otvos L Jr, Vetter SW, Koladia M, Knappe D, Schmidt R, Ostorhazi E, Kovalszky I, Bionda N, Cudic P, Surmacz E, Wade JD, Hoffmann R. Otvos L Jr, et al. Amino Acids. 2014 Apr;46(4):873-82. doi: 10.1007/s00726-013-1650-6. Epub 2013 Dec 24. Amino Acids. 2014. PMID: 24366600

9

Designer adiponectin receptor agonist stabilizes metabolic function and prevents brain injury caused by HIV protease inhibitors.

Pepping JK, Otvos L Jr, Surmacz E, Gupta S, Keller JN, Bruce-Keller AJ. Pepping JK, et al. Among authors: otvos l jr. J Neuroimmune Pharmacol. 2014 Jun;9(3):388-98. doi: 10.1007/s11481-014-9529-1. Epub 2014 Feb 23. J Neuroimmune Pharmacol. 2014. PMID: 24562631 Free PMC article.

10

Development of a pharmacologically improved peptide agonist of the leptin receptor.

Otvos L Jr, Terrasi M, Cascio S, Cassone M, Abbadessa G, De Pascali F, Scolaro L, Knappe D, Stawikowski M, Cudic P, Wade JD, Hoffmann R, Surmacz E. Otvos L Jr, et al. Biochim Biophys Acta. 2008 Oct;1783(10):1745-54. doi: 10.1016/j.bbamcr.2008.05.007. Epub 2008 May 21. Biochim Biophys Acta. 2008. PMID: 18555805 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

273 results

Search Page